Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

This study has been completed.
Information provided by:
Bristol-Myers Squibb Identifier:
First received: January 12, 2005
Last updated: April 7, 2011
Last verified: April 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2007
  Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)